Skip to content
sugarisadrug.com
  • Home
  • Diabetes
  • Health News
  • General Sugar
  • Food Choices
  • Insulin
  • Mental Health
  • Stop Eating Sugar
  • Stop Killing Yourself
  • Fructose
  • Sugar Science

Category: Diabetes

1248-OR: Triglycerides in Low-Density Lipoprotein and Coronary Artery Disease Risk: Evidence from Mendelian Randomization

June 13, 2026 by sugaradmin

Introduction and Objective: Triglyceride in low-density lipoprotein (TG-LDL) was considered a novel biomarker for coronary artery disease (CAD) from observational studies. We aimed to explore the causal relationship between TG-LDL levels and both overall and sex-specific CAD risk in individuals of European ancestry.Methods: We analyzed 487,759 European-ancestry participants from the UK Biobank and performed a […]

Read More
DiabetesLeave a Comment on 1248-OR: Triglycerides in Low-Density Lipoprotein and Coronary Artery Disease Risk: Evidence from Mendelian Randomization

1254-OR: Orforglipron vs. Dapagliflozin in Type 2 Diabetes Inadequately Controlled with Metformin

June 13, 2026 by sugaradmin

Introduction and Objective: ACHIEVE-2 (NCT06192108) assessed the efficacy and safety of orforglipron (OFG), an oral non-peptide GLP-1 receptor agonist (RA), versus dapagliflozin (DAPA), an SGLT2 inhibitor, in people with T2D inadequately controlled with metformin.Methods: This 40-week, phase 3, open-label (OFG dose-blinded), randomized study included adults with T2D (HbA1c ≥7.0 to ≤10.5%) taking metformin (≥1500 mg/day) […]

Read More
DiabetesLeave a Comment on 1254-OR: Orforglipron vs. Dapagliflozin in Type 2 Diabetes Inadequately Controlled with Metformin

1245-OR: PCSK9 Inhibitors Are Associated with a Lower Risk of Incident Diabetes: A Global Real-World Analysis

June 13, 2026 by sugaradmin

Introduction and Objective: Statins are first-line lipid-lowering agents but increase the risk of incident diabetes mellitus (DM). Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are an alternative, though real-world data on their diabetogenic risk are limited. We compared incident DM risk among users of PCSK9i and other lipid-lowering therapies.Methods: Using the TriNetX Global Collaborative Network, […]

Read More
DiabetesLeave a Comment on 1245-OR: PCSK9 Inhibitors Are Associated with a Lower Risk of Incident Diabetes: A Global Real-World Analysis

1241-OR: A Cross-Species Systematic Atlas of cGAS-STING Signaling: Regulation of Retinal Angiogenesis in Physiological and Pathophysiological Contexts

June 12, 2026 by sugaradmin

Introduction and Objective: Abnormal angiogenesis is the leading cause of vision loss globally, but current anti-angiogenic treatments are unsatisfactory and incompetent. Thus, novel therapies targeting angiogenesis are urgently needed. Previously, we revealed a positive association between cGAS-STING signaling and angiogenic factors in the mouse model with ischemic retinopathy. However, whether cGAS-STING signaling regulates retinal angiogenesis […]

Read More
DiabetesLeave a Comment on 1241-OR: A Cross-Species Systematic Atlas of cGAS-STING Signaling: Regulation of Retinal Angiogenesis in Physiological and Pathophysiological Contexts

1227-OR: RAY1225, a Biweekly Biased GLP-1/GIP RA for Weight Management: A Phase 2 Trial in Chinese Overweight/Obese Adults (REBUILDING-1)

June 12, 2026 by sugaradmin

Introduction and Objective: RAY1225, a bi-weekly GLP-1/GIP receptor agonist, has demonstrated substantial potential for glycemic control and weight loss in phase 1 study. This phase 2 trial assessed the efficacy and safety of RAY1225 compared with placebo in Chinese overweight or obese adults without diabetes.Methods: In this multicenter, randomized, double-blind, placebo-controlled phase 2 trial, nondiabetic […]

Read More
DiabetesLeave a Comment on 1227-OR: RAY1225, a Biweekly Biased GLP-1/GIP RA for Weight Management: A Phase 2 Trial in Chinese Overweight/Obese Adults (REBUILDING-1)

1242-OR: Cannabinoid Receptor 2 Agonism Decreases Retinal Inflammation and Is Neuroprotective in Diabetic Retinopathy Models

June 12, 2026 by sugaradmin

Introduction and Objective: Early diabetic retinopathy (DR) is associated with inflammation and retinal neurodegeneration, which begin prior to overt microvascular pathology. Cannabinoid (CB) receptor 2 agonism has been shown to have anti-inflammatory and neuroprotective properties in the central nervous system. This study tested the potential of CB2-selective agonists HU-308 and CB65 to reduce inflammation and […]

Read More
DiabetesLeave a Comment on 1242-OR: Cannabinoid Receptor 2 Agonism Decreases Retinal Inflammation and Is Neuroprotective in Diabetic Retinopathy Models

1235-OR: Gestational Diabetes Diagnosis Using Continuous Glucose Monitoring at 24–28 Weeks’ Gestation

June 12, 2026 by sugaradmin

Introduction and Objective: Data are limited as to whether continuous glucose monitoring (CGM) can be used to accurately diagnose gestational diabetes mellitus (GDM). We aimed to develop GDM diagnostic criteria based on CGM metrics at 24-28 weeks’ gestation.Methods: Planned analysis of a longitudinal, multi-site prospective cohort of gravidas without pregestational diabetes who wore a blinded […]

Read More
DiabetesLeave a Comment on 1235-OR: Gestational Diabetes Diagnosis Using Continuous Glucose Monitoring at 24–28 Weeks’ Gestation

1228-OR: First-in-Human Study Demonstrates GIP Receptor (GIPR) Antagonist AT7687 as Well-Tolerated and Suitable for Once-Weekly Subcutaneous Injection for Treatment in People Living with Obesity

June 12, 2026 by sugaradmin

Introduction and Objective: AT7687 is a first-in-class peptide GIPR antagonist validated as anti-obesity therapy in obese monkeys, as monotherapy and in combination with liraglutide and cagrilintide. This randomized, double-blind, placebo-controlled study evaluated the safety, pharmacokinetics (PK), and pharmacodynamics of AT7687 (AT).Methods: In the single ascending dose (SAD) part, 60 participants randomized 6:2 by cohort received […]

Read More
DiabetesLeave a Comment on 1228-OR: First-in-Human Study Demonstrates GIP Receptor (GIPR) Antagonist AT7687 as Well-Tolerated and Suitable for Once-Weekly Subcutaneous Injection for Treatment in People Living with Obesity

1265-OR: Tirzepatide: Effect on Insulin Resistance and Human Fat Cells

June 12, 2026 by sugaradmin

Introduction and Objective: We tested the hypothesis that tirzepatide (TZ), a dual GLP-1/GIP agonist, improves metabolic health independent of weight loss via GIP effects on adipose cells. Dual GLP-1/GIP agonists are known to lower blood glucose to a greater degree than selective GLP-1 agonists. We quantified insulin resistance (IR) and adipose cell function after 6 […]

Read More
DiabetesLeave a Comment on 1265-OR: Tirzepatide: Effect on Insulin Resistance and Human Fat Cells

1264-OR: Launch of the First Fully Remote Type 1 Diabetes Screening Program: Integration of a Novel, Scalable Genetic Risk Score and At-Home Monitoring with Autoantibody Testing and Psychosocial Support

June 12, 2026 by sugaradmin

Introduction and Objective: Early type 1 diabetes (T1D) detection is vital to prevent DKA, which affects 60% of pediatric cases. However, traditional screening relies on invasive blood draws, limiting accessibility for young children. We launched the first “fully remote” T1D screening program designed for large-scale implementation using a novel genetic stratification tool alongside online monitoring […]

Read More
DiabetesLeave a Comment on 1264-OR: Launch of the First Fully Remote Type 1 Diabetes Screening Program: Integration of a Novel, Scalable Genetic Risk Score and At-Home Monitoring with Autoantibody Testing and Psychosocial Support

Posts navigation

Older posts
Newer posts

Recent Posts

  • After GLP-1s Quit Working, He Lost 80 Pounds with a Simple Procedure
  • Perimenopause: Can Regular Exercise Improve Your Symptoms?
  • GLP-1 Side Effects vs. Benefits: Real Patient Experiences
  • Menopause: ADHD Medications May Reduce Brain Fog
  • Migraine: Endometriosis Linked to More Than Double the Risk

Recent Comments

  • A WordPress Commenter on SUCROSE: “PURE” ENERGY AT A PRICE

Archives

  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • November 2024
  • October 2024
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • May 2017

Categories

  • Celebrity Health
  • Diabetes
  • Food Choices
  • Fructose
  • General Sugar
  • Glucose
  • Health News
  • Insulin
  • Mental Health
  • Natural Unrefined Sugar
  • Stop Eating Sugar
  • Stop Killing Yourself
  • Sucrose
  • Sugar Science

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
  • Home
  • Diabetes
  • Health News
  • General Sugar
  • Food Choices
  • Insulin
  • Mental Health
  • Stop Eating Sugar
  • Stop Killing Yourself
  • Fructose
  • Sugar Science

© 2026 Sugar is a DRUG | Sugar Addiction Awareness